Assembly Biosciences, Inc. (ASMB) stock
ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/309% below fair value
$22.50+1.21 (+5.68%)
Close on Nov 17, 2026Market cap $458.11MP/E –Yield –
Assembly Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Assembly Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.65M, up 8.3% year over year. For fiscal 2025 it was $64.81M, up 15.9% from the year before. Over ten years it grew 13.4% a year on average. The highest annual figure on record is $106.82M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.81M | +15.9% |
| FY2024 | Dec 31, 2024 | $55.93M | +14.4% |
| FY2023 | Dec 31, 2023 | $48.90M | -30.1% |
| FY2022 | Dec 31, 2022 | $69.98M | +2.1% |
| FY2021 | Dec 31, 2021 | $68.52M | -35.9% |
| FY2020 | Dec 31, 2020 | $106.82M | +24.6% |
| FY2019 | Dec 31, 2019 | $85.76M | +17.9% |
| FY2018 | Dec 31, 2018 | $72.74M | +64.5% |
| FY2017 | Dec 31, 2017 | $44.23M | +33.6% |
| FY2016 | Dec 31, 2016 | $33.09M | +80.3% |
| FY2015 | Dec 31, 2015 | $18.36M | +71.3% |
| FY2014 | Dec 31, 2014 | $10.72M | -28.7% |
| FY2013 | Dec 31, 2013 | $15.03M | -23.0% |
| FY2012 | Dec 31, 2012 | $19.51M | -22.8% |
| FY2011 | Dec 31, 2011 | $25.28M | +1265.9% |
| FY2010 | Dec 31, 2010 | $1.85M | -37.1% |
| FY2009 | Dec 31, 2009 | $2.94M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.92M | -7.5% |
| Q1 FY2026 | Mar 31, 2026 | $14.90M | +0.3% |
| Q4 FY2025 | Dec 31, 2025 | $17.25M | +20.8% |
| Q3 FY2025 | Sep 30, 2025 | $16.59M | +22.7% |
| Q2 FY2025 | Jun 30, 2025 | $16.13M | -0.8% |
| Q1 FY2025 | Mar 31, 2025 | $14.85M | +25.0% |
| Q4 FY2024 | Dec 31, 2024 | $14.28M | +29.7% |
| Q3 FY2024 | Sep 30, 2024 | $13.52M | +24.9% |
| Q2 FY2024 | Jun 30, 2024 | $16.26M | +29.8% |
| Q1 FY2024 | Mar 31, 2024 | $11.88M | -18.3% |
| Q4 FY2023 | Dec 31, 2023 | $11.01M | -34.7% |
| Q3 FY2023 | Sep 30, 2023 | $10.82M | -40.3% |
| Q2 FY2023 | Jun 30, 2023 | $12.52M | -29.6% |
| Q1 FY2023 | Mar 31, 2023 | $14.55M | -15.4% |
| Q4 FY2022 | Dec 31, 2022 | $16.85M | +14.3% |
| Q3 FY2022 | Sep 30, 2022 | $18.13M | -1.9% |
| Q2 FY2022 | Jun 30, 2022 | $17.79M | +6.2% |
| Q1 FY2022 | Mar 31, 2022 | $17.21M | -7.3% |
| Q4 FY2021 | Dec 31, 2021 | $14.75M | -56.0% |
| Q3 FY2021 | Sep 30, 2021 | $18.47M | -31.4% |
| Q2 FY2021 | Jun 30, 2021 | $16.75M | -28.2% |
| Q1 FY2021 | Mar 31, 2021 | $18.55M | -19.5% |
| Q4 FY2020 | Dec 31, 2020 | $33.51M | +48.2% |
| Q3 FY2020 | Sep 30, 2020 | $26.94M | +23.9% |
| Q2 FY2020 | Jun 30, 2020 | $23.33M | +24.7% |
| Q1 FY2020 | Mar 31, 2020 | $23.05M | +1.5% |
| Q4 FY2019 | Dec 31, 2019 | $22.62M | +6.4% |
| Q3 FY2019 | Sep 30, 2019 | $21.74M | +13.7% |
| Q2 FY2019 | Jun 30, 2019 | $18.70M | +4.8% |
| Q1 FY2019 | Mar 31, 2019 | $22.70M | +56.1% |
| Q4 FY2018 | Dec 31, 2018 | $21.25M | +100.5% |
| Q3 FY2018 | Sep 30, 2018 | $19.11M | +74.8% |
| Q2 FY2018 | Jun 30, 2018 | $17.84M | +47.1% |
| Q1 FY2018 | Mar 31, 2018 | $14.54M | +37.5% |
| Q4 FY2017 | Dec 31, 2017 | $10.60M | +22.9% |
| Q3 FY2017 | Sep 30, 2017 | $10.93M | +23.7% |
| Q2 FY2017 | Jun 30, 2017 | $12.13M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.57M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.62M | – |
| Q3 FY2016 | Sep 30, 2016 | $8.83M | – |
See a number that looks wrong?